BioSpace News Archive

FDA

Mereo BioPharma Receives FDA Fast Track Designation for Alvelestat for Treatment of Alpha-1 Antitrypsin Deficiency (AATD)-associated Lung Disease

Mereo BioPharma Group plc today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its investigational oral neutrophil elastase inhibitor, alvelestat (MPH-966).

October 17, 2022
·
6 min read
Pharm Country

Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at the National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit

Zynerba Pharmaceuticals, Inc. presented a poster at the 2022 National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit being held October 17-18, 2022, in Washington, D.C.

October 17, 2022
·
6 min read
Genetown

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - October 17, 2022

EyePoint Pharmaceuticals, Inc. announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2016 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635.

October 17, 2022
·
2 min read
BioForest

Athira Pharma Advances Phase 2/3 LIFT-AD Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients Following Independent, Unblinded Interim Analysis

Athira Pharma, Inc. today announced that following an unblinded interim efficacy and futility analysis, an independent data monitoring committee recommended continuation of the LIFT-AD study of fosgonimeton (ATH-1017) in patients with mild-to-moderate Alzheimer’s disease (AD).

October 17, 2022
·
8 min read
Drug Development

Leap Therapeutics Announces First Patient Enrolled in DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients

Leap Therapeutics, Inc. (NASDAQ: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that the first patient has been enrolled in the Phase 2 DeFianCe study evaluating DKN-01, Leap’s anti-Dickkopf-1 antibody.

October 17, 2022
·
5 min read
Business

ImmuneID Appoints Jessica Atkinson as Chief Business Officer

ImmuneID today announced the appointment of Jessica Atkinson as Chief Business Officer, where she will oversee business activities as part of ImmuneID leadership with dual goals of advising on the company’s current direction and exploring and maximizing external collaboration opportunities for its aiSPIRE platform.

October 17, 2022
·
2 min read
Business

Asep Inc. Signs Agreement with Bohai Biomedical Technology Development Co., Ltd., to Establish the Feasibility of Peptide-based Oral Rinse for the Chinese Market

Asep Medical Holdings Inc. is very pleased to announce that it has signed a Feasibility Study Agreement with the Chinese firm Bohai Biomedical Technology Development Co. Ltd., (Bohai Biomedical).

October 17, 2022
·
5 min read
Biotech Bay

40 CROs Select Veeva Vault CTMS to Drive Clinical Trial Operations

Veeva Systems (NYSE: VEEV) today announced that 40 contract research organizations (CROs) selected Veeva Vault CTMS to deliver faster and more efficient trials to sponsors, which includes four of the top six global CROs.

October 17, 2022
·
3 min read
Galapagos to host its R&D Update 2022 in New York on 4 November 2022

Galapagos NV announced that it will host its R&D Day 2022 for analysts, investors and financial press on Friday, 4 November2022.

October 17, 2022
·
2 min read
Drug Development

Bavarian Nordic’s COVID-19 Booster Vaccine Candidate Demonstrates Durable Antibody Response Six Months After Vaccination in Phase 2 Clinical Trial

Bavarian Nordic A/S announced the results of a six-month follow-up analysis from a Phase 2 clinical trial of ABNCoV2, a VLP-based, non-adjuvanted COVID-19 booster vaccine candidate.

October 17, 2022
·
5 min read